Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA) versus AAP+APA in patients with advanced prostate cancer with noncastrate testosterone levels: (LACOG 0415).

Fernando C. Maluf,Andre Poisl Fay,Vinícius Carrera Souza,Fabio A.B. Schutz,Oren Smaletz,Daniel Herchenhorn,Vanessa Fabricio,Rosemarie Gidekel,E. Cronemberger,Murilo Luz,Suelen Patrícia dos Santos Martins,David Queiroz Borges Muniz,F Franke,Fabio A. Peixoto,Flavio Mavignier Cárcano,Andrea J. Pereira de Santana Gomes,Felipe Melo Cruz,Rafaela Gomes,Paulo Ricardo Santos Nunes Filho,Gustavo Werutsky

Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA) versus AAP+APA in patients with advanced prostate cancer with noncastrate testosterone levels: (LACOG 0415).

2020

5505Background: ADT combined with AAP, APA, enzalutamide or docetaxel are among the standard treatment options to patients (pts) with hormone sensitive advanced/metastatic prostate cancer (PC). How...

Keywords:

Urology
Testosterone
Abiraterone acetate
Apalutamide
in patient
Prostate cancer
Pathology
Medicine
Randomized controlled trial
Prednisone

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations